Discontinue Allopurinol Immediately and Monitor Closely
You should stop allopurinol immediately in this patient with isolated ALT elevation (150 U/L) and elevated anion gap, as this pattern suggests potential drug-induced liver injury that requires urgent intervention. 1
Immediate Management Steps
1. Stop Allopurinol Now
- The FDA label explicitly warns that allopurinol "is not an innocuous drug" and requires careful monitoring for hepatotoxicity 1
- Drug-induced liver injury from allopurinol can progress to severe hypersensitivity reactions with significant morbidity 1, 2
- The isolated ALT elevation (with normal AST) is a concerning pattern that warrants immediate drug cessation 3
2. Repeat Liver Function Tests in 48-72 Hours
- Check ALT, AST, total bilirubin, alkaline phosphatase, and albumin 3
- If ALT continues to rise or exceeds 3× upper limit of normal (typically >120 U/L), this confirms drug-induced hepatotoxicity requiring permanent discontinuation 4
- Monitor for development of eosinophilia, rash, or fever—warning signs of allopurinol hypersensitivity syndrome 5, 1
3. Investigate the Elevated Anion Gap
- The elevated anion gap is concerning and may indicate:
- Lactic acidosis from hepatic dysfunction
- Renal impairment (check creatinine clearance)
- Metabolic acidosis from another cause 6
- Obtain: lactate, ketones, renal function, and consider arterial blood gas if clinically indicated
- The combination of hepatotoxicity and metabolic derangement suggests systemic drug toxicity 1
Clinical Context and Pitfalls
Why This Matters
The normal uric acid level indicates the allopurinol was therapeutically effective, but this does not justify continuing a hepatotoxic medication. Efficacy does not outweigh safety concerns when hepatotoxicity develops 1.
Common Mistake to Avoid
Do not continue allopurinol at a reduced dose or "watch and wait" with ongoing therapy. The FDA guidance and clinical evidence consistently show that:
- Hepatotoxicity can occur at any dose 1, 2
- Bone marrow depression and severe hypersensitivity can develop as early as 6 weeks after initiation 1
- Rechallenge after liver injury carries significant risk 4
The Isolated ALT Pattern
An ALT elevation with normal AST suggests hepatocellular injury rather than cholestatic disease 3, 7. While fatty liver disease is the most common cause of mild ALT elevation in the general population, the temporal relationship with allopurinol initiation and the presence of metabolic derangement (elevated anion gap) strongly implicate the drug 7.
Next Steps After Discontinuation
Monitor for Resolution
- ALT should begin declining within 1-4 months after stopping allopurinol 8
- If ALT normalizes, this confirms drug-induced injury
- If ALT continues rising or fails to improve after 2-4 weeks, pursue alternative diagnoses with hepatology consultation 3
Alternative Urate-Lowering Therapy
Once liver function normalizes completely:
- Switch to febuxostat as the preferred alternative xanthine oxidase inhibitor 9, 10
- Febuxostat does not require dose adjustment for mild-moderate renal impairment and has a different safety profile 9
- Start at 40 mg daily and titrate to achieve serum urate <6 mg/dL 9
- Do not rechallenge with allopurinol given documented hepatotoxicity 4, 1
If Febuxostat is Contraindicated
Consider uricosuric agents (probenecid) if creatinine clearance >50 mL/min, or benzbromarone in select cases with hepatology oversight 9, 10
Key Monitoring Parameters Going Forward
- Repeat LFTs weekly until normalized, then monthly for 3 months 8
- Check CBC to exclude bone marrow suppression 1
- Assess renal function and correct the anion gap abnormality
- When starting alternative urate-lowering therapy, use colchicine 0.5-1 mg daily for flare prophylaxis for 6 months 9
The priority is preventing progression to severe allopurinol hypersensitivity syndrome, which carries 20-25% mortality 5. The elevated anion gap adds urgency to this clinical scenario, suggesting systemic metabolic derangement that may herald more severe toxicity.